MazenNoureddinMDMHSc
Gastroenterology • Houston, TXHepatology & Liver Transplantation
Transplant Hepatologist, Houston Methodist Hospital, Director Houston Research Institute
Dr. Noureddin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1155 Dairy Ashford Road
Ste 200
Houston, TX 77079Phone+1 281-809-3234Fax+1 281-809-3287
Education & Training
Duke School of MedicineMHSc, Master's Health Sciences in Clinical Research, 2009 - 2018
University of California (San Diego) Medical CenterFellowship, Gastroenterology, 2011 - 2013
Clinical Center at the National Institutes of HealthFellowship, Transplant Hepatology, 2009 - 2011
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2005 - 2008
University of Aleppo Faculty of MedicineClass of 2002
Certifications & Licensure
CA State Medical License 2007 - 2025
TX State Medical License 2022 - 2025
VA State Medical License 2008 - 2012- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Top Doctors Pasadena Magazine 2014-2018
- Visionary in Health Care American Liver Foundation, 2016
Clinical Trials
- The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease Patients Start of enrollment: 2014 Jun 01
- Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis Start of enrollment: 2015 Jun 01
Publications & Presentations
PubMed
- Alcohol-related liver and extrahepatic malignancies: burden of disease and socioeconomic disparities in 2019.Pojsakorn Danpanichkul, Kanokphong Suparan, Nathorn Chaiyakunapruk, Thanida Auttapracha, Siwanart Kongarin
European Journal of Gastroenterology & Hepatology. 2025-02-01 - 11 citationsMASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up.Minsun Kwak, Hyun-Seok Kim, Zhenghui Gordon Jiang, Yee Hui Yeo, Hirsh D Trivedi
Hepatology. 2025-01-01 - Combination Treatment in MASLD: The Next Frontier.Emmanuel A Tsochatzis, Mazen Noureddin
Clinical Gastroenterology and Hepatology. 2025-01-01
Journal Articles
- NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances.Noureddin M1,2, Vipani A3, Bresee C4, Todo T5, Kim IK5, Alkhouri N6, Setiawan VW7, Tran T8,3, Ayoub WS8,3, Lu SC8,3, Klein AS5, Sundaram V8,3, Nissen NN5., American Journal of Gastrenterology, 6/8/2018
- NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications for Liver Transplant and Ethnic and Gender VariancesTsuyoshi Todo, Walid S Ayoub, Naim Alkhouri, Nicholas N Nissen, Vinay Sundaram, Shelly C Lu, Mazen Noureddin, Aarshi Vipani, Tram Tran, Andrew S Klein, Nature
Press Mentions
Boston Pharmaceuticals to Announce Positive Phase 2 Data on Efimosfermin Alfa (BOS-580) in F2/F3 MASH During Late-Breaking Oral Presentation at AASLD 2024, the Liver Meeting®November 15th, 2024- Exploring FIB-4 for Fibrosis Risk AssessmentOctober 2nd, 2024
- Q&A: MASH Experts Emphasize Using Noninvasive Tests to Assess Response to RezdiffraAugust 9th, 2024
- Join now to see all
Other Languages
- Arabic, Farsi, Spanish
External Links
- Houston Methodist Hospitalhttps://www.houstonmethodist.org/doctor/mazen-noureddin/
- Houston Research Institute https://www.houstonresearchinstitute.com/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
